Here we show a dual tumor targeting approach for GBM, simultaneously targeting EGFRvIII and HER2 by DNA-encoded bispecific T cell engagers, to demonstrate suppression of immune escape in a heterogeneous GBM model. The gene discussed is ERBB2; the disease is neoplasm.